A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Optimization Study of BHV-1530 as Monotherapy and in Combination With Other Anti-Cancer Agents in Adult Participants With Advanced or Metastatic Solid Tumors
This study tests a new experimental drug called BHV-1530, both by itself and alongside another medicine called cemiplimab, in adults with advanced solid tumors. Researchers want to find the best and safest doses of these treatments to help patients whose cancer has grown or returned.
Adults aged 18 and older with advanced or metastatic solid tumors who have tried previous treatments may be able to join. The study is currently recruiting new participants.
Participants will receive the study treatment, either as BHV-1530 alone or combined with cemiplimab, and will have their health closely monitored. Different groups receive different combinations of these medicines.
This study takes place at 17 sites across 1 country: the United States. It is currently active and recruiting new participants.
- 1Testing a new cancer drug called BHV-1530
- 2Open to adults with advanced solid tumors
- 3Currently recruiting participants at 17 sites in the United States
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.